BlackRock Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

BlackRock Group’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-4,161	Closed	-$23K	–	3115
2016 Q1	$23K	Buy	4,161 +1,734	+71%	+$22.5K	﹤0.01%	3020
2015 Q4	$42K	Sell	2,427 -82	-3%	-$1.96K	﹤0.01%	2848
2015 Q3	$53K	Buy	2,509 +610	+32%	+$20.9K	﹤0.01%	2841
2015 Q2	$94K	Buy	1,899 +510	+37%	+$30.5K	﹤0.01%	2762
2015 Q1	$109K	Buy	1,389 +491	+55%	+$30.5K	﹤0.01%	2639
2014 Q4	$54K	Buy	+898	New	+$45.1K	﹤0.01%	2772

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's OREX Position: Q2 2016 in Review

BlackRock Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 4,161 shares — an estimated $23K sold.

BlackRock Group first reported a position in OREX in Q4 2014 and held it in 6 quarters. The position peaked at $109K in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

BlackRock Group reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
BlackRock Group sold 4,161 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $23K.
BlackRock Group first reported a position in Orexigen Therapeutics, Inc. in Q4 2014 and held it in 6 quarters.
BlackRock Group's Orexigen Therapeutics, Inc. position peaked at $109K in Q1 2015.
73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on BlackRock Group's 13F filing for Q2 2016, filed 10 Aug 2016.